Abstract: Papillary thyroid cancer (PTC) is the most common pathological type of thyroid cancer, always with favorable prognosis. However, the incidence of thyroid cancer recently appeared to be an increasing trend. Because of the increased amount of patients, refractory thyroid cancer was not rare anymore. Hence, we are facing a big challenge how to manage and treat the increasing number of patients. BRAF V600E mutation is a classic DNA-relative biomarker for PTC, and widely used in preoperative diagnosis and evaluation of prognosis. As a potential therapeutic target, it attracted more and more attention. Recognizing BRAF V600E mutation can help us to know oncogenesis and biological behavior of PTC better and provide profitable treatment and management.

Key words: BRAF V600E mutation, Papillary thyroid cancer, Oncogenesis, Aggressiveness, Prognosis, Survival analysis